Aortic valve sector growth provides attractive opportunities safe treatment

Aortic valve is a natural valve in the heart, which regulates the flow of blood from the left ventricle to the aorta. In a valvular heart disease, such as aortic valve regurgitation or aortic valve stenosis, the functioning of the valve is compromised, creating the need for a replacement. As per the 2016 Interventional Cardiology Journal, Valvular Heart Diseases – Epidemiology and New Treatment Modalities, and the 2006 Valvular Heart Disease in Elderly Adults report published by Nkomo et al, the risk of VHD increases with age.

Now, among the two types of valves transplanted in the human body — mechanical and tissue/biological — the latter dominated the market during the historical period (2013–2017) in terms of sales volume as well as value. In terms of value, tissue/biological valves held almost 65.0% share in the aortic valve market. Such valves, which are made from tissues of other animals, are quite flexible and can last up to 20 years. Further, people transplanted with biological/tissue valves do not require additional medication.

Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/aortic-valve-market

Of the two types of procedures for aortic valve replacement, viz. open surgery and minimally-invasive surgery (MIS), the valves transplanted via MIS dominated the market in 2017 in terms of value. Further, even in MIS, there are two main approaches: transfemoral and transapical. Of these, the transfemoral approach consumed valves in the larger amount, contributing $2,397.8 million in revenue to the aortic valve market in 2017. It is further being predicted that the sale of aortic valves for transfemoral MIS will generate a revenue of $4,897.5 million by 2023.

Therefore, it is clear that the increase in the prevalence of VHD, driven by the growth of the geriatric population, will bode well for the market for aortic valves.